Biotech M&A Anomalies With Allan Shaw
Business Of Biotech
00:00
Oncology and Rare Diseases - Is That the De Facto Standard?
Oncology still owns like nearly half the attention of all small mid cap, small to mid cap bios. Is that just the de facto standard will be for some time? That's your safe bet. Or are there other areas, disease areas that perhaps will create or provide opportunity in the short term? No, it's what the market is right now. Neurology recently, there has been a serious emphasis there. I think they're the risks of development, you know, going back to safe or non-safe and biotech.
Transcript
Play full episode
